Physician

Andrew Smith, MD

According to 2025 Medicare claims, Andrew Smith, MD (NPI: 1164468955) practices allergy/immunology in the Salt Lake City-Murray, UT market, with the plurality of this provider's patient population coming from Salt Lake, UT. This provider's primary affiliated billing organization is ALLERGY ASSOCIATES OF UTAH, P.C. (NPI: 1801341961; TIN: 475146734) and primary practice location at 84093-1000.

Smith's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 282 traditional Medicare patients, billed 27,456 HCPCS/CPT codes, and received $488,352 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,685 prescription claims across 176 beneficiaries totaling $2,172,942 in drug costs, led by Icatibant (Icatibant Acetate). DME data shows 82 claims. Open Payments data shows 300 records totaling $226,991. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $58,186 to $488,352. Similarly, Part D prescription costs have risen steadily, from $10,503 to $2,172,942. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$244K$488K2017 Medicare payment: $58,186 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $86,686 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $178,902 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $168,413 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $249,788 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $289,829 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $244,544 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $488,352 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017894,431$58,186
20181206,113$86,686
201924810,500$178,902
20202249,801$168,413
202125613,770$249,788
202227217,122$289,829
202326916,242$244,544
202428227,456$488,352

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$1.1M$2.2M2015 Drug cost: $10,503 (USD; Tot_Drug_Cst)2016 Drug cost: $99,198 (USD; Tot_Drug_Cst)2017 Drug cost: $651,353 (USD; Tot_Drug_Cst)2018 Drug cost: $91,124 (USD; Tot_Drug_Cst)2019 Drug cost: $85,651 (USD; Tot_Drug_Cst)2020 Drug cost: $1,039,469 (USD; Tot_Drug_Cst)2021 Drug cost: $252,258 (USD; Tot_Drug_Cst)2022 Drug cost: $263,890 (USD; Tot_Drug_Cst)2023 Drug cost: $323,132 (USD; Tot_Drug_Cst)2024 Drug cost: $2,172,942 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201528121$10,503
201648219$99,198
201764305$651,353
201878404$91,124
2019116652$85,651
20201581,253$1,039,469
20211591,158$252,258
20221501,194$263,890
20231661,472$323,132
20241761,685$2,172,942

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$66K$132K2017 Medicare payment: $37,395 (USD; DME_Suplr_Mdcr_Pymt_Amt)2018 Medicare payment: $51,904 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $56,847 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $131,606 (USD; DME_Suplr_Mdcr_Pymt_Amt)2021 Medicare payment: $93,392 (USD; DME_Suplr_Mdcr_Pymt_Amt)2022 Medicare payment: $101,726 (USD; DME_Suplr_Mdcr_Pymt_Amt)2023 Medicare payment: $9,946 (USD; DME_Suplr_Mdcr_Pymt_Amt)2024 Medicare payment: $51,444 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/R36$37,395
2018N/R44$51,904
2019N/R53$56,847
2020N/R101$131,606
2021N/R86$93,392
2022N/R123$101,726
2023N/R49$9,946
2024N/R82$51,444

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more188313$90
94010Test to measure expiratory airflow and volume173277$19
95165Professional service for preparation and provision of 1 or more antigens853,960$10
95117Professional service for multiple injections of allergen891,399$8
96160Administration and interpretation of patient-focused health risk assessment263491$2

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
IcatibantIcatibant Acetate1133$115,515
XolairOmalizumab26728$70,151
Trelegy ElliptaFluticasone/Umeclidin/Vilanter843,270$69,297
TezspireTezepelumab-Ekko13364$55,875
Dupixent PenDupilumab13364$44,987

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS CodeHCPCS DescriptionSupplier Rental IndicatorTotal Supplier BeneficiariesTotal Supplier ClaimsTotal Medicare Payment Amount
J1576Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mgNN/R12$37,746
J7677Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgramNN/R17$13,027
Q0513Pharmacy dispensing fee for inhalation drug(s); per 30 daysNN/R22$569
E0570Nebulizer, with compressorYN/R20$75
A7003Administration set, with small volume nonfiltered pneumatic nebulizer, disposableNN/R11$26

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.283$151,788AstraZeneca Pharmaceuticals LP
Research PaymentsReported research-related payment or transfer-of-value amount.17$75,203Novartis Pharmaceuticals Corporation
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Andrew Smith, MD?

Tedicare shows public-source Medicare data for Andrew Smith, MD (NPI 1164468955), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew Smith, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew Smith, MD?

Andrew Smith, MD is linked to ALLERGY ASSOCIATES OF UTAH, P.C. (billing NPI 1801341961) in the available physician profile data.

Does Andrew Smith, MD have Open Payments data?

Andrew Smith, MD has 300 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.